<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918150</url>
  </required_header>
  <id_info>
    <org_study_id>HXF-CT2-20111</org_study_id>
    <nct_id>NCT01918150</nct_id>
  </id_info>
  <brief_title>Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII</brief_title>
  <acronym>EVIDENCE II</acronym>
  <official_title>A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hexacath, France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hexacath, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety, at 24 months, of the
      TITAN2 stent to any bare-metal stent (BMS) in Cobalt-Chromium in a population presenting an
      indication for these stents among 40% of which present an acute coronary syndrome (ACS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EVIDENCE II trial is a post-registration study for TITAN2 stent initiated on the request
      of the French Health Authorities' (HAS) in June 2009 for the next renewal of registration on
      the list of reimbursable products and services in France.

      The study is so designed to compare the effectiveness and safety at 24 months of the TiTAN2
      versus Cobalt-Chromium BMS randomly assigned. As a part of the secondary objectives, a
      cost-effectiveness study is also planned.

      The comparators are cobalt chromium stents CE marketed and free of any coating (nude BMS).

      All will be used in their authorized indications.

      A total of 1350 patients will be included over a period of a year or more and followed for 24
      months for the primary endpoint (MACE rate at 24 months in the overall population :
      cumulative incidence of cardiac deaths, MI and target lesion revascularization (TLR)).

      Patients will also be clinically followed at 6 and 12 months . Medico economic datas are to
      collect at a similar time point.

      An independent Clinical Event Committee, unaware of the treatment allocation, will be in
      charge of the adjudication of all the cardiac events including MACE (main
      objective)collected.

      The calculation of the number of subjects specifies that 1350 patients are needed to meet the
      primary endpoint of the study.

      Enrolled patient will be randomly assigned in a 2:1 fashion as follows :

        -  900 patients in TITAN2 arm including 360 with ACS (Arm A)

        -  450 patients in Cobalt-chromium arm including 180 with ACS (Arm B) In case of more than
           one stent needed, the protocol mandated using the same stent than the one assigned in
           all the lesions treated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>24 months</time_frame>
    <description>The primary endpoint (MACE) is the composite of cardiac death, (Myocardial Infarction) MI and target lesion revascularization (TLR).
These events will be collected post-procedure during the patient's hospitalization and at 6 , 12 and 24 month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medico economic evaluation</measure>
    <time_frame>24 months</time_frame>
    <description>Data collection of acts and diagnosis specific codes related to any adverse event with hospitalization in relation with the endoprothesis allocated.
It will be then analyzed by an dedicated expert who will be able to appreciate a cost/efficiency rate for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR ) rate</measure>
    <time_frame>24 months</time_frame>
    <description>Any study stent restenosis leading to a procedure or a surgery to treat it.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate</measure>
    <time_frame>24 months</time_frame>
    <description>Stent thrombosis will be evaluated as per the ARC classification (ie degree of evidence and time to event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success of the procedure</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as an efficient reintroduction of the blood flow in the target vessel post angioplasty.
It's a &quot;YES/NO&quot; question.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Silent Myocardial Infarction</condition>
  <condition>Stable Angina</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>TITAN 2 stent - Hexacath France</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving Titan 2 stents (percutaneous coronary intervention)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cobalt-Chromium BMS - Any firm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Titan 2 stents</intervention_name>
    <description>The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.</description>
    <arm_group_label>TITAN 2 stent - Hexacath France</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cobalt-Chromium Bare Metal Stents</intervention_name>
    <description>The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.</description>
    <arm_group_label>Cobalt-Chromium BMS - Any firm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with symptomatic de novo coronary lesion involving one or two vessels

          -  Patient presenting a lesion with &gt; 50% stenosis

          -  Patient who must undergo a percutaneous coronary intervention (PCI) in the indications
             of Cobalt-chromium bare metal stents and TITAN2 stents and being able to be
             indifferently treated with one or the other of these stents.

          -  Written informed consent

          -  Expected survival &gt; 2 years

          -  Patient reachable by phone throughout the duration of the study.

        Exclusion Criteria:

          -  Pregnant/Lactating women

          -  Women of childbearing potential (last menstrual period &lt;12 months) not using effective
             contraception

          -  Patient under legal protection

          -  Indication of coronary artery bypass graft surgery (CABG)

          -  History of coronary artery bypass graft surgery (CABG)

          -  Intrastent restenosis lesion

          -  Bifurcation lesion with the exception of those treated with a standardized approach
             (provisional stenting with final kissing in the side branch)

          -  Left main coronary lesion

          -  Ostial target lesion

          -  Previous drug-eluting stenting

          -  Previous bare metal stenting or balloon angioplasty in the 12 months prior the
             inclusion; if this implantation involved the target artery, separate the new implanted
             stent at a distance â‰¥ 10 mm.

          -  History of stent thrombosis

          -  Heavily calcified lesion

          -  Use of the Rotablator

          -  Left ventricular ejection fraction (LVEF) &lt; 30%

          -  Cardiac arrest, cardiogenic shock or severe heart failure (Killip stage III or IV)

          -  Severe chronic renal failure (creatinine clearance &lt;30 ml min)

          -  Cardiac or renal transplantation

          -  Major surgery within the last 14 days

          -  Surgery scheduled within 30 days (non-ACS patients) or 12 months (if ACS) at the time
             of the randomization

          -  History of major bleeding

          -  Pathology with major risk of bleeding or any condition, allergy or intolerance which
             is incompatible with anticoagulation and / or extended antiplatelet therapy

          -  Known allergy to Titanium, Nickel, Cobalt or Chromium

          -  Patient currently participating in another clinical trial

          -  Non-compliant patient (treatment and follow-up)

          -  Patient living abroad
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles RIOUFOL, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon- Bron - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique La Fourcade</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Bois Bernard</name>
      <address>
        <city>Bois-Bernard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CÃ´te de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Louis Pasteur</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Albert Schweitzer</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier LaÃ«nnec</name>
      <address>
        <city>Creil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier GÃ©nÃ©ral</name>
      <address>
        <city>Haguenau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier DÃ©partemental</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lagny</name>
      <address>
        <city>Lagny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Bron</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Beauregard</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Les Fontaines</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelles Cliniques Nantaises</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>NÃ®mes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Alleray Labrouste</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Val de GrÃ¢ce</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Pau</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Martin</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Claude Galien- ICPS</name>
      <address>
        <city>Quincy-sous-SÃ©nart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Laurent</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Hilaire</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint-Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Toulon La Seyne</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Valence</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Cobalt</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

